Priveterra Acquisition announced the completion of its business combination with AEON Biopharma, a Phase 3 stage-ready biopharmaceutical company developing a proprietary neurotoxin with initial focus on preventive treatments for episodic and chronic migraines along with other debilitating medical conditions.
After adjourning the shareholder vote eight times, the SPAC poured an additional $125 million into the deal, providing more than enough financing to cover the minimum cash condition.
Source: Priveterra Acquisition Completes AEON Biopharma Merger